Table 2 Effect of medical therapy on visual field defects in patients with macroprolactinomas
Author (year) | n(M/F) | VFD n(%) | VFD improved n(%) | Treatment | Unique study characteristics |
|---|---|---|---|---|---|
Ferrari CI (1997) [29] | 85 (29/56) | 12/85 (14 %) | 6/12 (50 %) | CAB | |
Colao A (1997) [22] | 23 (8/15) | 10/23 (43 %) | 9/10 (90 %) | CAB | Low dose CAB |
Pinzone JJ (2000) [101] | 34 (34/0) | 14/19 (74 %) | 11/14 (79 %) | DA | Primary medical therapy |
Pontikides N (2000) [23] | 12 (6/6) | 4/12 (33 %) | 3/4 (75 %) | CAB | CAB as 1st line therapy |
Sibal L (2002) [35] | 35 (35/0) | 18/35 (51 %) | 18/18 (100 %)a | DA | Medical therapy |
Corsello SM (2003) [17] | 10 (10/0) | 7/10 (70 %) | 6/7 (86 %) | CAB | CAB for giant prolactinomas |
Shimon I (2007) [16] | 12 (12/0) | 7/12 (58 %) | 7/7 (100 %) | CAB | Giant prolactinomas |
Total | 211 (134/77) | 72/196 (37 %) | 60/72 (83 %) |